In the News

Oncode researchers are featured regularly in the (national) media. This shows that their hard work goes beyond the interest of the Oncology community. We are proud of how our Oncode researchers explain their science to the general public. On this page we share the highlights of their media appearances.

11 - 11 - 2021

DNA Repair is slowing down aging 

Oncode Investigator Jan Hoeijmakers is quoted in Volkskrant in an article about the genetic advantages of a redfish species that can live up to 200 years. In Hoeijmakers' view, these findings add to the growing pile of evidence that DNA repair plays an important role in slowing down aging.

17 - 11 - 2021

7 million euros to investigate why cancer is coming back after treatment

Oncode Investigator Alexander van den Oudenaarden is interviewed by MedNet about the new PERSIST-SEQ consortium. This consortium will investigate why cancer often comes back after treatment and then becomes resistant to the treatment that was successful in the first place. As project lead of the PERSIST-SEQ consortium, van den Oudenaarden describes the role of Oncode Institute in this project. 

30 - 11 - 2021 

Less radical treatment for vulva cancer

Zorgkrant writes about a new Oncode Clinical proof of Concept project by Oncode Investigator Sjoerd van der Burg. He will focus on less radical treatments for vulva cancer. Vulva cancer is becoming more common in young women. With a grant from Oncode Institute, he and his team will investigate the effect of the less invasive checkpoint-inhibitor immunotherapy.

17 - 12 - 2021 

Whole genome sequencing

Oncode Investigator Emile Voest talks about the benefits of whole genome sequencing. He describes how this can help determine standard and experimental treatments for cancer patients.

02 - 02 - 2022

Hans Clevers starts new position at Roche

Oncode Investigator Hans Clevers appeared on the Dutch TV Programme Op1 to talk about his switch to the Swiss biopharmaceutical company Roche.

11 - 01 - 2022 

Promising treatment

Zorgkrant writes about Oncode Researcher Julie Nonnekens receiving the Starting Grant from the European Research Council (ERC). The grant will be used for her research on targeted radionuclide therapy for cancer, a promising treatment for metastatic cancer.

08 - 02 - 2022

Launch Laigo Bio writes about Oncode Institute and ArgoBio launching Laigo Bio: a targeted biotech for protein degradation with programmes in oncology and neurological disorders. Oncode Investigator Madelon Maurice is the Principal Investigator for this biotech.

Outsmarting cancer

impacting lives


Outsmarting cancer

impacting lives